Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned

Nine out of ten metastatic prostate cancer (PCa) patients will develop osseous metastases. Of these, every second will suffer from skeletal-related events (SRE). SRE are associated with an increased risk for death, which is markedly increased in the presence of pathological fracture. Moreover, healt...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Christian Thomas, Georg Bartsch, Christian Walter, Hendrik Borgmann, Maximilian Peter Brandt, Thomas Höfner, Axel Haferkamp, Igor Tsaur
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2016-08-01
coleção:	Dentistry Journal
Assuntos:	zoledronic acid denosumab prostate cancer osteonecrosis
Acesso em linha:	http://www.mdpi.com/2304-6767/4/3/28
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!